October 14, 2016
1 min read

Juvéderm Volift effective in treating nasolabial folds up to 1 year

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Juvéderm Volift with lidocaine was effective in treating moderate-to-severe nasolabial folds and well-tolerated by patients, with effects lasting to 1 year, according to study results recently published in Dermatologic Surgery.

Researchers studied 70 patients (mean age, 49 years; 94% women) with moderate-to-severe nasolabial folds (NLF) recruited between June 2012 and January 2013 from three centers in Germany and the Netherlands. All patients received initial treatments with the hyaluronic acid dermal filler Juvéderm Volift with lidocaine (VYC-17.5L, Allergan plc) formulated with 17.5 mg/mL of low and high molecular weight hyaluronic acid at baseline (day 0). Twenty-eight patients received top-up treatment at day 14. Follow-ups were at 1, 9 and 12 months after the last treatment.

Validated photonumeric NLF Severity Scale was used to measure investigator-assessed change in NLF severity over 12 months, the primary endpoint. Patients received a mean volume injected of 3.0 ± 1.0 mL for both nasolabial folds combined. Sixty-five patients completed the study.

Investigator-assessed NLF severity at 12 months saw a significant improvement, and investigators and patients reported high satisfaction with the treatment during the study.

Patient-reported pain, swelling and bruising had generally low mean scores after the initial and top-up treatments. Two adverse events, including one patient with redness, swelling and decreased sensitivity, which resolved after 4 days, and one patient with swelling, which resolved after 48 hours, were reported.

“VYC-17.5L is highly effective in treating moderate-to-severe NLFs with results lasting up to 1 year,” the researchers concluded “As fillers are uniquely suited to treat specific indications and regions of the face, aesthetic clinicians can use the results of this study to help create tailored treatment algorithms and long-term treatment plans to attain optimal treatment outcomes for their patients.”  by Bruce Thiel

Disclosure: Sattler reports being a lecturer, study investor and scientific advisory board member for Allergan plc, which sponsored the study. Please see the full study for the other researchers’ relevant financial disclosures.